SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

M V KargA BoschD KannenkerilK StriepeC OttM P SchneiderF Boemke-ZelchP LinzA M NagelJ TitzeM UderRoland Erich Schmieder

Published in: Cardiovascular diabetology (2018)

SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in tissue sodium content of the skin after 6 weeks. This observation point to a decrease of total sodium content in patients with type 2 diabetes prone to cardiovascular complications, that might be mitigated by SGLT-2 inhibition. Trial registration The study was registered at http://www.clinicaltrials.gov (NCT02383238) retrospectively registered.

Keyphrases

clinical trial
study protocol
phase iii
soft tissue
gestational age
preterm birth